Loading clinical trials...

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma

NCT06573151•Ruijin Hospital

View on ClinicalTrials.gov

Summary

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody and P-GemOx in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Detailed Description

This study aims to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus P-GemOx in relapsed or refractory NKTCL and find the optimal treatment regimen for patients with relapsed refractory NKTCL. Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus P-GemOx, and then PET evaluation.

Eligibility

Age

14 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Confirmed histological diagnosis of NKTCL nasal type
•2. The subject had received prior adequate anti-lymphoma therapy containing asparaginase
•3. Age 14-75 years old
•4. Expected to live longer than 3 months
•5. At least one measurable/evaluable site after diagnostic biopsy before treatment start
•6. ECOG performance status of 0-2
•7. Adequate hematological and organ function; i.e. ANC \>1000 cells /mmc, platelet counts \> 50.000/mmc, Hemoglobin \> 9 g/dl AST, ALT \<3 x ULN; serum bilirubin \< 1.5x ULN (patient with Gilbert disease can be enrolled) Serum creatinine \< 2 x ULN or creatinine clearance \> 50ml/min
•8. Tumor tissue (fresh preferred, archival tissue is also acceptable)
•9. For women of childbearing potential a negative pregnancy test on day 1 of cycle 1 and agree to adopt adequate measure to avoid pregnancy during study treatment and for at least one year from EOT.
•10. For men agreement to remain abstinent or to use barrier contraception
+1 more criteria

Exclusion Criteria

•1. Confirmed histological diagnosis of aggressive NK cell leukemia
•2. Evidence of suspect of CNS disease.
•3. Has an active autoimmune disease that has required systemic treatment in past 2-years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), including but not limited to myotonia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associate with antiphospholipid syndrome, wegener's granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis. The following exception are allowed: patients with autoimmune related hypothyroidism or type I diabetes mellitus who are on stable treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
•4. Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed.
•5. Active infection requiring systemic therapy
•6. History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis
•7. Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina.
•8. History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer).
•9. HBsAg, HCV or HIV positivity. Positive serology is admitted for HBV and HCV but DNA/RNA test must be negative
•10. Pregnant or lactating women
+2 more criteria

Key Dates

Start Date

September 1, 2024

Primary Completion Date

July 1, 2027

Completion Date

July 1, 2027

Last Updated

August 27, 2024

Enrollment

ESTIMATED participants

Conditions

Lymphoma

Interventions

Selinexor, anti-PD-1 antibody and P-GemOx

DRUG

Contacts

Weili Zhao, Prof.

CONTACT

008602164370045 zwl_trial@163.com

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

U69-CART-Cells For R/R T-ALL